MD Anderson and Kymab announce research and development strategic partnership in immuno-oncology
Kymab, a leading human monoclonal antibody biopharmaceutical company, and The University of Texas MD Anderson Oncology Research for Biologics and Immunotherapy Translation (ORBIT) unit today announced a strategic cancer drug discovery and development alliance. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - January 7, 2016 Category: Cancer & Oncology Source Type: news

Lymphoma/Myeloma symposium for patients and caregivers set for Feb. 6
Patients with lymphoma or myeloma and their caregivers will have access to leading experts in this field of cancer during an upcoming symposium to be held Feb. 6 in San Antonio. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - January 6, 2016 Category: Cancer & Oncology Source Type: news

Sugar in Western diets increases risk for breast cancer tumors and metastasis
The high amounts of dietary sugar in the typical Western diet may increase the risk of breast cancer and metastasis to the lungs, according to a study at The University of Texas MD Anderson Cancer Center. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 31, 2015 Category: Cancer & Oncology Source Type: news

Immune suppressor cells identified for advanced prostate cancer
Immune suppressor cells called MDSCs (myeloid-derived suppressor cells) may be important in developing treatments for advanced prostate cancer, according to a study at The University of Texas MD Anderson Cancer Center. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 21, 2015 Category: Cancer & Oncology Source Type: news

Pancreas cancer liquid biopsy flows from blood-borne packets of tumor genes
Pancreatic cancer tumors spill their molecular secrets into the blood stream, shedding their complete DNA and RNA wrapped inside protective lipid particles that make them ripe for analysis with a liquid biopsy, researchers at The University of Texas MD Anderson Cancer Center report online at the Annals of Oncology. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 17, 2015 Category: Cancer & Oncology Source Type: news

Mastectomy plus reconstruction has highest rate of complication, complication-related costs of guideline-concordant therapies for early breast cancer
n a review of guideline-concordant treatment modalities for women with early stage breast cancer, mastectomy and reconstruction had the highest rate of complications and complication-related costs, regardless of age. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 10, 2015 Category: Cancer & Oncology Source Type: news

Delaying chemotherapy in breast cancer patients reduces overall survival, especially for those with triple-negative breast cancer
Postponing the start of adjuvant chemotherapy for more than 90 days following surgery may significantly increase risk of death for breast cancer patients, particularly those with triple-negative breast cancer (TNBC), according to a new study from The University of Texas MD Anderson Cancer Center. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 10, 2015 Category: Cancer & Oncology Source Type: news

Multiple myeloma patient study shows promise for natural killer cells
A first-in-human Phase I study of multiple myeloma patients combined expanded cord blood-derived natural killer cells with transplantation of a patient's own stem cells and high-dose chemotherapy with little or none of the side effects seen with current treatments. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 8, 2015 Category: Cancer & Oncology Source Type: news

Study shows ibrutinib superior to traditional chemotherapy in untreated chronic leukemia patients
A multi-center, international, randomized, Phase III study of older untreated patients with chronic lymphocytic leukemia (CLL) demonstrated that ibrutinib, a kinase inhibitor, is significantly more effective than traditional chemotherapy with chlorambucil. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 7, 2015 Category: Cancer & Oncology Source Type: news

Loss of enzyme promotes tumor progression in endometrial cancer
Scientists have shown for the first time why loss of the enzyme CD73 in human cancer promotes tumor progression. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 7, 2015 Category: Cancer & Oncology Source Type: news

Depressed head and neck cancer patients three-and-one-half times less likely to survive, have higher recurrence risk
Depression is a significant predictor of five-year survival and recurrence in head and neck cancer patients, according to a new study from The University of Texas MD Anderson Cancer Center. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 3, 2015 Category: Cancer & Oncology Source Type: news

Boehringer Ingelheim and MD Anderson join forces to discover new treatment approaches for pancreatic cancer
Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a collaboration focused on developing innovative medicines for pancreatic ductal adenocarcinoma (PDAC). (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 2, 2015 Category: Cancer & Oncology Source Type: news

Complete surgical excision is the most effective treatment for breast implant-associated anaplastic large-cell lymphoma
The optimal treatment approach for most women with breast implant-associated anaplastic large-cell lymphoma (BI-ALCL) is complete surgical excision of the implant and surrounding capsule, according to an international study led by researchers at The University of Texas MD Anderson Cancer Center. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 1, 2015 Category: Cancer & Oncology Source Type: news

Two MD Anderson faculty named as prestigious AAAS Fellows
Distinguished contributions to understanding p53 tumor suppression in stem cells and breakthrough advances in treating breast cancer have earned two scientists at The University of Texas MD Anderson Cancer Center membership in a notable association of scholars. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 23, 2015 Category: Cancer & Oncology Source Type: news

Tumor-suppressor p53 regulates protein that stifles immune attack on cancer
A crucial tumor-thwarting gene protects an immune attack against lung cancer by blocking the key to an off switch on T cells, the customized warriors of the immune system, a team led by researchers at The University of Texas MD Anderson Cancer Center reports in the Journal of the National Cancer Institute. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 20, 2015 Category: Cancer & Oncology Source Type: news